Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Laboratory preparation of monochloramine for environmental research: A comparison of four commonly used protocols.

Environmental research·2021
Same author

Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline.

The European respiratory journal·2021
Same author

A dynamic nomogram for predicting diabetic macular edema in type 2 diabetes patients based on plasma cytokines.

Aging·2021
Same author

Bloodstream Infections Caused by Carbapenem-Resistant <i>Enterobacterales</i>: Risk Factors for Mortality, Antimicrobial Therapy and Treatment Outcomes from a Prospective Multicenter Study.

Infection and drug resistance·2021
Same author

Mitochondrial uncoupler MB1-47 is efficacious in treating hepatic metastasis of pancreatic cancer in murine tumor transplantation models.

Oncogene·2021
Same author

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)<sup>1</sup>.

Autophagy·2021

Related Experiment Video

Updated: Jun 6, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

Understanding DP receptor antagonism using a CoMSIA approach.

Lan Mu1, Joacy Aguiar, Ali Ardati

  • 1Sanofi Aventis US, 1041 Route 202-206 N, Bridgewater, NJ 08807-0800, United States.

Bioorganic & Medicinal Chemistry Letters
|December 15, 2010
PubMed
Summary

This study developed computational models to identify potent prostaglandin D2 receptor antagonists. The models reveal that optimal binding requires two hydrogen-bond acceptors separated by a hydrophobic center, guiding future drug design.

More Related Videos

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis
07:48

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis

Published on: July 3, 2015

Related Experiment Videos

Last Updated: Jun 6, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis
07:48

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis

Published on: July 3, 2015

Area of Science:

  • Medicinal Chemistry
  • Computational Chemistry
  • Pharmacology

Background:

  • Prostaglandin D2 (DP) receptor antagonists are crucial for treating allergic inflammatory diseases.
  • Developing novel DP receptor antagonists requires understanding structure-activity relationships.

Purpose of the Study:

  • To establish robust quantitative structure-activity relationship (QSAR) models for 2,6-substituted-4-monosubstituted aminopyrimidine DP receptor antagonists.
  • To identify key molecular features essential for high binding affinity and antagonist potency.

Main Methods:

  • Comparative Molecular Similarity Indices Analysis (CoMSIA) was employed to build QSAR models.
  • Two-component and three-component CoMSIA models were developed and validated.
  • Molecular descriptors related to steric, electronic, and hydrophobic properties were analyzed.

Main Results:

  • A three-component CoMSIA model demonstrated high predictive power (Q(2) = 0.70, R(2) = 0.91).
  • Optimal binding involves two hydrogen-bond acceptors positioned approximately 8 Å apart.
  • A significant hydrophobic region between these acceptors enhances antagonist potency.

Conclusions:

  • The established CoMSIA models accurately predict the activity of novel DP receptor antagonists.
  • The identified pharmacophore, featuring specific hydrogen-bond acceptors and a hydrophobic center, provides a rational basis for designing more effective DP receptor antagonists.
  • These findings facilitate the discovery of new therapeutic agents for allergic conditions.